ETBX-011

Ad5 (E1-, E2b-) CEA(6D) vaccine · NantCell, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ETBX-011, covering 2024-08-06 to 2024-08-06. Get the full timeline:

Most recent: Clinical Trial Update: QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer [Phase 1, Phase 2]

See pricing